Medicud Srl

Medicud Srl, founded in 2020 in Rome, Italy, specializes in medical devices that provide innovative solutions for wound care. The company launched its flagship product, Dryum, which is a single-use, mechanically powered incisional negative pressure wound therapy device. Medicud has successfully completed 3 deals and is not known to have undergone any significant changes in business strategy or operations. The company was founded by individuals whose specific identities are not publicized.Medicud specializes in innovative medical devices, primarily focusing on a single-use, mechanically powered incisional negative pressure wound therapy (i-NPWT) device known as Dryum. Launched in 2020, Dryum provides a user-centered, ultraportable solution designed to deliver constant negative pressure to surgical wounds, thereby reducing complications and enhancing healing. This device addresses specific challenges in wound care, such as high costs and the cumbersome nature of existing therapies, ultimately aiming to improve patient outcomes.Medicud operates on a direct-to-consumer and B2B transaction model, primarily selling its flagship product, Dryum, to healthcare institutions and professionals. The company’s revenue structure involves direct sales to hospitals and clinics, leveraging partnerships for distribution in various markets. The anticipated market entry for Dryum is set for 2025, targeting a segment of the substantial market of over 230 million incisional surgeries performed annually worldwide.Medicud plans to launch its flagship product, Dryum, in 2025, following its market entry and the completion of regulatory approvals for the CE mark and FDA certification. Additionally, Medicud aims to expand into European markets and other regions with significant surgical activities, capitalizing on the demand for advanced wound care solutions.

1. Seed

   Apr 1, 2025

   Amount

   $0.8M

   Investors

   Locked